Extracorporeal membrane oxygenation in children with COVID-19 and PIMS-TS during the second and third wave

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10445265" target="_blank" >RIV/00064165:_____/22:10445265 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10445265

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=M_LRVQwTiP" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=M_LRVQwTiP</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S2352-4642(22)00065-7" target="_blank" >10.1016/S2352-4642(22)00065-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Extracorporeal membrane oxygenation in children with COVID-19 and PIMS-TS during the second and third wave

Popis výsledku v původním jazyce

During the first wave of the COVID-19 pandemic, the European Extracorporeal Life Support Organization (ELSO) established a prospective survey1 including 52 European neonatal and paediatric centres and reported the use of extracorporeal membrane oxygenation (ECMO) in seven children with acute respiratory distress syndrome (ARDS) related to COVID-19 and paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS; also known as multisystem inflammatory syndrome in children). All European neonatal and paediatric ECMO centres affiliated with ELSO were included in the survey. Non-ELSO centres were also invited and included as representation for neonatal and paediatric ECMO centres in their respective country. The study was approved by the Maastricht University Ethical Committee (the coordinating centre) and registered at ClinicalTrials.gov (NCT04366921). Data were collected once per week and were reported as anonymised and deidentified using password-protected datasheets, and hence individual parent and patient consent was waived.

Název v anglickém jazyce

Extracorporeal membrane oxygenation in children with COVID-19 and PIMS-TS during the second and third wave

Popis výsledku anglicky

During the first wave of the COVID-19 pandemic, the European Extracorporeal Life Support Organization (ELSO) established a prospective survey1 including 52 European neonatal and paediatric centres and reported the use of extracorporeal membrane oxygenation (ECMO) in seven children with acute respiratory distress syndrome (ARDS) related to COVID-19 and paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS; also known as multisystem inflammatory syndrome in children). All European neonatal and paediatric ECMO centres affiliated with ELSO were included in the survey. Non-ELSO centres were also invited and included as representation for neonatal and paediatric ECMO centres in their respective country. The study was approved by the Maastricht University Ethical Committee (the coordinating centre) and registered at ClinicalTrials.gov (NCT04366921). Data were collected once per week and were reported as anonymised and deidentified using password-protected datasheets, and hence individual parent and patient consent was waived.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The Lancet: Child and Adolescent Health

ISSN

2352-4642

e-ISSN

2352-4642

Svazek periodika

6

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

"e14"-"e15"

Kód UT WoS článku

000821081500002

EID výsledku v databázi Scopus

2-s2.0-85127006622